Immunotherapies that rely on reinvigorating T cells to patrol the body, detect cancerous cells, and eliminate them have shown the potential for long-lasting cures. Despite their initial success, however, immunotherapies have been effective only for some cancers and for some patients. To improve outcomes, Dr. Birnbaum has developed a new method to match T cells with their antigen targets on cancer cells by engineering viruses to use T cell recognition as a means of cell entry. This technology will be applicable to a wide range of cancers, including ones for which immunotherapy is not currently effective.